Neuroaid

From Wikipedia, the free encyclopedia - View original article

 
  (Redirected from NeuroAid)
Jump to: navigation, search

Neuroaid (also NeuroAiD, MLC 601, or MLC 901) is a claimed treatment for stroke sold by Moleac Pte Ltd, a biopharmaceutical company in Singapore. There are two versions: Neuroaid (MLC601) and Neuroaid II (MLC901), with differing blends of ingredients.[1] The ingredients total 14 for both, with nine derived from plants and five from animals.[2]

List of ingredients[edit]

List of ingredients in Neuroaid MLC 601 [3][4]
Radix astragali (Milk-vetch or Goats-thorn)
Radix salviae miltiorrhizae (red sage or Chinese sage)
Radix paeoniae rubra (Chinese peony or common garden peony)
Rhizoma chuanxiong
Radix angelicae sinensis (dong quai or female ginseng)
Carthamus tinctorius(Safflower)
Prunus persica (peach)
Radix Polygalae
Rhizoma acori tatarinowi
Buthus martensii (scorpion)*
Hirudo (leech)*
Eupolyphaga Seu Steleophaga (cockroach or tu bie cong)*
Calculus Bovis Synthetic/Artifactus (cow bile)*
Cornu saigae tataricae (horn of an endangered antelope species)*

Mechanisms of action[edit]

Neuroaid has been shown to stimulate the secretion of brain-derived neurotrophic factor (BDNF). The in vitro and in vivo results show that it makes cells more resistant against glutamate aggression, increases neurite outgrowth and connectivity as well as reduces the infarct volume.[1]

Research[edit]

Biochemistry[edit]

In 2008, a study showed Neuroaid does not modify hemostasis, hematology, and biochemistry in normal subjects and stroke patients.[5] This clinical trial found no interaction of NeuroAid with aspirin. Moreover, the treatment does not increase the risk of bleeding, thrombosis, and has no effect on blood pressure, liver, or kidneys functions.[5]

Laboratory studies[edit]

A study in rodents indicated that MLC 901 had neuroprotective, neuroplasticity and neuroproliferative (neurogenesis) effects.[1]

Clinical Trials[edit]

Chronic stage of stroke[edit]

In 2009, a paper summarized unpublished data on a clinical trial comparing Neuroaid to another traditional Chinese medicine (Buchang Naoxintong Jiaonang) on 605 patients in post stroke recovery. Patients started Neuroaid at least two weeks and less than 6 month after their stroke. The research showed that patients taking Neuroaid had a greater improvement in a measure of functionality at 1 month of treatment, whereas no significant benefit was observed in either group in terms of neurological deficit score and individual scores. Nausea and vomiting were reported as side effects.[6][7]

A 2013 systematic review noted limitations in the available evidence, but concluded that there was some evidence that Neuroaid (MLC 601) "could be effective in further improving functional independence and motor recovery and is safe for patients with primarily nonacute stable stroke."[8]

Acute stage of stroke[edit]

A study conducted in Asia on 1100 patients, initiated on Neuroaid within 72 hours of the stroke onset as an add on to medication concluded that MLC601 is statistically no better than placebo in improving outcomes at 3 months when used among patients with acute ischemic stroke of intermediate severity.[6][9][10]

Pilot studies[edit]

The double blind placebo-controlled randomized Phase II Pilot study called TIERS was conducted on 40 patients receiving MLC601 3 times a day for four weeks. The treatment was initiated less than one month after the stroke. The results published in 2009 showed that there were no significant statistical differences between the placebo and the Neuroaid groups.[11]

References[edit]

  1. ^ a b c Heurteaux C, Gandin C, Borsotto M, et al. (June 2010). "Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo". Neuropharmacology 58 (7): 987–1001. doi:10.1016/j.neuropharm.2010.01.001. PMID 20064536. 
  2. ^ Broussalis E, Trinka E, Killer M, Harrer A, McCoy M, Kraus J (2012). "Current therapies in ischemic stroke. Part B. Future candidates in stroke therapy and experimental studies". Drug Discov Today 17 (13-14): 671–84. doi:10.1016/j.drudis.2012.02.011. PMID 22405898. 
  3. ^ Composition of Neuroaid, Neuroaid website, retrieved 15 May 2013
  4. ^ Marie Germaine Bousser, David Picard, Xuemin Shi "Combination therapy for treatment of patients with neurological disorders and cerebral infarction" Patent number EP 1993580 A1 published 26 November 2008
  5. ^ a b Gan R, Lambert C, Lianting J, et al. (2008). "Danqi Piantan Jiaonang does not modify hemostasis, hematology, and biochemistry in normal subjects and stroke patients". Cerebrovascular Diseases 25 (5): 450–6. doi:10.1159/000126919. PMID 18417963. 
  6. ^ a b Chen C, Venketasubramanian N, Gan RN, et al. (March 2009). "Danqi Piantang Jiaonang (DJ), a traditional Chinese medicine, in poststroke recovery". Stroke 40 (3): 859–63. doi:10.1161/STROKEAHA.108.531616. PMID 19164787. 
  7. ^ Shaista Anwar Sidddiqi and Ayeesha Kamran Kamal, "Use of Traditional Chinese Medication for post-stroke recovery", Journal of Pakistan Medical Association September 2011
  8. ^ Siddiqui, Fahad Javaid; Venketasubramanian, Narayanaswamy; Chan, Edwin Shih-Yen; Chen, Christopher (2013). "Efficacy and Safety of MLC601 (NeuroAiD®), a Traditional Chinese Medicine, in Poststroke Recovery: A Systematic Review". Cerebrovascular Diseases 35: 8–17. doi:10.1159/000346231. PMID 23548914. 
  9. ^ Chen, C. L. H.; Young, S. H. Y.; Gan, H. H.; Singh, R.; Lao, A. Y.; Baroque, A. C.; Chang, H. M.; Hiyadan, J. H. B.; Chua, C. L.; Advincula, J. M.; Muengtaweepongsa, S.; Chan, B. P. L.; de Silva, H. A.; Towanabut, S.; Suwanwela, N. C.; Poungvarin, N.; Chankrachang, S.; Wong, K. S. L.; Eow, G. B.; Navarro, J. C.; Venketasubramanian, N.; Lee, C. F.; Bousser, M.-G. (18 June 2013). "Chinese Medicine Neuroaid Efficacy on Stroke Recovery: A Double-Blind, Placebo-Controlled, Randomized Study". Stroke 44 (8): 2093–2100. doi:10.1161/STROKEAHA.113.002055. PMID 23780952. 
  10. ^ http://clinicaltrials.gov/ct2/results?term=neuroaid
  11. ^ Kong KH, Wee SK, Ng CY, et al. (2009). "A double-blind, placebo-controlled, randomized phase II pilot study to investigate the potential efficacy of the traditional chinese medicine Neuroaid (MLC 601) in enhancing recovery after stroke (TIERS)". Cerebrovascular Diseases 28 (5): 514–21. doi:10.1159/000247001. PMID 19816018.